NOX4 and pulmonary fibrosis: Several NOX inhibitors have been analyzed in recent comprehensive reviews (Augsburger et al., 2019; Begum et al., 2022; Chocry and Leloup, 2020; Elbatreek et al., 2021) but only a few selective antagonists for NOX2 and NOX4 isoforms have been synthesized, and only one (GKT137831, a specific inhibitor of NOX1 and NOX4) is in human clinical trials (phase 2) for pulmonary fibrosis and cirrhosis (Begum et al., 2022).